REN-001 is under clinical development by Reneo Pharmaceuticals and currently in the Phase I and Phase III in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect REN-001’s likelihood of approval (LoA) and phase transition for Carnitine Palmitoyltransferase II (CPT- II)Deficiency took place on 06 Sep 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway.

In addition, the same event on 06 Sep 2022 increased REN-001’s Phase Transition Success Rate (PTSR) for Long-Chain 3-Hydroxyacyl-CoA Dehydrogenase (LCHAD) Deficiency.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their REN-001 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

REN-001 overview

HPP-593 (REN-001) is under development for the treatment of McArdle disease (glycogen storage disorder 5), primary mitochondrial myopathy, MELAS syndrome metabolic syndromes and fatty acid oxidation disorders (FAODs) with confirmed mutations in the Carnitine palmitoyltransferase II deficiency (CPT2), Very long-chain Acyl-CoA dehydrogenase deficiency (VLCAD), Long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency (LCHAD) or Trifunctional Protein Deficiency (TFP). It is administered through the oral route. The drug candidate acts by targeting peroxisome proliferator-activated delta receptor (PPAR).

HPP-593 was also under development for the treatment of musculoskeletal disorders, dyslipidemia and type 2 diabetes.

Reneo Pharmaceuticals overview

Reneo Pharmaceuticals, a biotechnology company that focused on developing treatments for orphan diseases. The company is headquartered in United States.

Quick View REN-001 LOA Data

Report Segments
  • Innovator
Drug Name
  • REN-001
Administration Pathway
  • Oral
Therapeutic Areas
  • Central Nervous System
  • Genetic Disorders
  • Metabolic Disorders
  • Musculoskeletal Disorders
Key Developers
Highest Development Stage
  • Phase III

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.